Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol inhaler and formoterol + aclidinium crossover PK study in COPD
2007-003648-31Phase 2Completed
- Sponsor
- Almirall
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of formoterol and aclidinium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Almirall. Primary endpoint: Relative bioavailability of formoterol. Started Feb 2008; status: completed.
02
Drugs
formoterolaclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-003648-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003648-31.